Safety and Efficacy of KPI-121 in Subjects With DED

PHASE3CompletedINTERVENTIONAL
Enrollment

901

Participants

Timeline

Start Date

July 10, 2018

Primary Completion Date

February 5, 2020

Study Completion Date

February 5, 2020

Conditions
Kerato Conjunctivitis Sicca
Interventions
DRUG

KPI-121 Ophthalmic Suspension

KPI-121 Ophthalmic Suspension

DRUG

Vehicle

Vehicle for KPI-121 0.25% ophthalmic suspension

Trial Locations (81)

10013

Investigator #105, New York

11793

Investigator #132, Wantagh

14618

Investigator #108, Rochester

15122

Investigator #277, West Mifflin

16066

Investigator #224, Cranberry Township

17601

Investigator #200, Lancaster

18704

Investigator #156, Kingston

23502

Investigator #119, Norfolk

27262

Investigator #102, High Point

27603

Investigator #163, Raleigh

27704

Investigator #217, Durham

27710

Investigator #149, Durham

28387

Investigator #282, Southern Pines

28803

Investigator #264, Asheville

30076

Investigator #268, Roswell

30260

Investigator #136, Morrow

32256

Investigator #265, Jacksonville

33484

Investigator #262, Delray Beach

33603

Investigator #189, Tampa

33773

Investigator #157, Largo

33901

Investigator #279, Fort Myers

34613

Investigator #184, Brooksville

35294

Investigator #133, Birmingham

36301

Investigator #278, Dothan

38119

Investigator #127, Memphis

40206

Investigator #195, Louisville

40220

Investigator #168, Louisville

40517

Investigator #274, Lexington

44115

Investigator #137, Cleveland

45040

Investigator #171, Mason

45242

Investigator #269, Cincinnati

45247

Investigator #142, Cincinnati

46260

Investigator #128, Indianapolis

46290

Investigator #250, Indianapolis

47150

Investigator #125, New Albany

57701

Investigator #240, Rapid City

60046

Investigator #151, Lake Villa

60169

Investigator #187, Hoffman Estates

60616

Investigator #266, Chicago

63090

Investigator #131, Washington

63128

Investigator #123, St Louis

63131

Investigator #106, St Louis

Investigator #126, St Louis

64133

Investigator #267, Kansas City

77055

Investigator #124, Houston

77204

Investigator #259, Houston

77573

Investigator #182, League City

Investigator #191, League City

78209

Site #177, San Antonio

78229

Investigator #258, San Antonio

78230

Investigator #186, San Antonio

78240

Investigator #176, San Antonio

78613

Investigator #174, Cedar Park

78681

Investigator #270, Austin

78731

Investigator #188, Austin

78734

Investigator #175, Lakeway

79902

Investigator #140, El Paso

80120

Investigator #218, Littleton

84041

Investigator #222, Layton

85032

Investigator #148, Phoenix

85224

Investigator #146, Chandler

85351

Investigator #276, Sun City

86301

Investigator #280, Prescott

89052

Investigator #281, Henderson

89123

Investigator #275, Las Vegas

89145

Investigator #263, Las Vegas

89148

Investigator #138, Las Vegas

90301

Investigator #155, Inglewood

90505

Investigator #107, Torrance

90805

Investigator #273, Long Beach

91204

Investigator #147, Glendale

91345

Investigator #130, Mission Hills

91702

Investigator #185, Azusa

92545

Investigator #272, Hemet

92562

Investigator #247, Murrieta

92663

Investigator #215, Newport Beach

92683

Investigator #213, Westminster

92705

Investigator #271, Santa Ana

92843

Investigator #143, Garden Grove

95670

Site #111, Rancho Cordova

01890

Investigator #219, Winchester

Sponsors
All Listed Sponsors
lead

Kala Pharmaceuticals, Inc.

INDUSTRY

NCT03616899 - Safety and Efficacy of KPI-121 in Subjects With DED | Biotech Hunter | Biotech Hunter